For the year ending 2025-12-31, TLSIW had $11,914K increase in cash & cash equivalents over the period. -$18,930K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -39,227 |
| Depreciation | 626 |
| Non-cash lease expense | 429 |
| Change in fair value of sepa, warrant and revenue base redemption liabilities | -4,086 |
| Change in fair value of contingent earnout liability | 2,743 |
| Pik interest | 800 |
| Stock-based compensation expense | 9,131 |
| Allowance for credit losses | 163 |
| Loss on disposal of property and equipment | -120 |
| Amortization of debt issuance costs | 1,049 |
| Accounts receivable | 1,634 |
| Inventory, net | -971 |
| Prepaid expenses and other assets | -840 |
| Deposits | -5 |
| Operating lease liabilities | -134 |
| Trade payables and accrued liabilities | 2,020 |
| Net cash used in operating activities | -18,012 |
| Purchases of property and equipment | 918 |
| Proceeds from disposal of property and equipment | 80 |
| Net cash used in investing activities | -838 |
| Proceeds from the issuance of common stock | 22,000 |
| Common stock issuance costs | 1,549 |
| Proceeds from the exercise of stock options for common stock | 510 |
| Proceeds from the issuance of common stock through employee stock purchase plan | 404 |
| Debt issuance costs | 520 |
| Proceeds from the issuance of debt | 10,000 |
| Payments on finance lease liabilities | 81 |
| Net cash provided by financing activities | 30,764 |
| Increase (decrease) in cash, cash equivalents and restricted cash | 11,914 |
| Cash, cash equivalents and restricted cash, beginning of period | 8,875 |
| Cash, cash equivalents and restricted cash, end of period | 20,789 |
TriSalus Life Sciences, Inc. (TLSIW)
TriSalus Life Sciences, Inc. (TLSIW)